ProKidney focuses on cell therapy for chronic kidney diseases, with REACT in Phase 3 trials and FDA's RMAT designation. Financially stable, with $446M in liquid assets and a 37-month cash runway, but ...
ProKidney (NASDAQ:PROK) said Monday that it has appointed a new CEO and plans to update its Phase 3 development program for its cell therapy REACT to focus on patients with advanced chronic kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback